Levemir: profile and news

New Long-Acting Insulin, Levemir, Shows Less Weight Gain ... Feb 8, 2006
MISSISSAUGA, ON -- February 8, 2006 -- Two million Canadians with diabetes will now have access to LevemirÂ® (insulin detemir), a new basal insulin with up to ... - DG News

Euro RSCG Tonic Takes On Diabetes Feb 28, 2006
The effort will compete with Novo Nordisk's Levemir, another 24-hour injection that was approved in 2005, and Pfizer's Exubera, an inhalable insulin powder ... - Adweek,

Sanofi Launches Apidra Just In Nick Of Time Mar 1, 2006
CM-CIC Securities analyst Francois Hamon. Says Lantus' facing tough competition from Levemir. Says positive newsflow seen further ... - New Ratings

Goldman Cuts Novo Nordisk EPS Estimates Feb 6, 2006
4Q results. Expects Novo's challenges to be ability to support larger US sales for Levemir launch, and increase in R&D. Says management ... - New Ratings

How Will We Dilute Insulin? Jan 31, 2006
...and parents.â€?. At press time, insulin detemir (Levemir) was not available. Like Lantus, Levemir is a long-acting basal insulin. - Diabetes Interview,

Stock market breaks 400 barrier Feb 3, 2006
After news that Novo product Levemir would be ready for a US rollout in the coming months, finance house SG Cowan replied with a decision to keep the company ... - Danmark.dk,

And Then There Were Some Jan 30, 2006
...â€œLantus and Levemir are very good [long-acting insulins],â€? says Edelman. â€œLevemir is probably closer to Ultralente than Lantus.â€?. ... - Diabetes Interview,

Thunder Bay test site Jan 7, 2006
Levemir has been approved by Health Canada and will be commercially available by February or March, said Dr. Asiru Abu-Bakare, an endocrinologist at the Port ... - Thunder Bay Chronicle Journal,

The insulin market â€“ moving with the times Jan 23, 2006
With the approval of its new long-acting insulin analogue, Levemir, in June last year, Novo Nordisk became the first company with a full range of insulin ... - In-PharmaTechnologist.com,

Biotechnology Industry Ends 2005 with Breakthrough Product ... Jan 18, 2006
Among the highlights, regulators approved three diabetes and cancer therapies including Novo Nordisk's Levemir, for treatment of diabetes mellitus, and Onyx's ... - Yahoo! News (press release)

Novo Nordisk Becomes Insulin Market Leader Nov 10, 2005
...diabetes. Additionally, we anticipate further growth with the launch of Levemir(R) (insulin detemir [rDNA origin] injection) in 2006. ... - PR Newswire (press release),

Novo Nordisk Japan Submits J-NDA for Insuline Detemir, Long-acting ... Dec 6, 2005
...approved in Switzerland in March 2004, the agent is approved in 55 countries and currently marketed in 24 countries worldwide under the trade name of Levemir. - Japan Corporate News (press release),

Insulin Gains at Novo Nordisk Nov 10, 2005
Nordisk, said. "Additionally, we anticipate further growth with the launch of Levemir (insulin detemir injection) in 2006. Treating ... - TheStreet.com

Market watch Nov 12, 2005
...weeks ago as well as their expectation that Novo's sale of insulin in the US will increase after the 2006 introduction of long-acting insulin analogue Levemir. ... - The Copenhagen Post,

Handelsbanken Ups Novo Nordisk Price Target Sep 27, 2005
Risks to estimates clearly to the downside depending on decision on US trauma trial and US launch of Levemir in 06. Trades +0.5% at DKK303. (JHC). ... - New Ratings

Novo Nordisk Sues sanofi-aventis for Insulin Delivery Device ... Sep 22, 2005
...suspension and 30% insulin aspart injection, [rDNA origin]), NovoLog(R) (insulin aspart [rDNA origin] injection) and soon-to-be-launched Levemir(R) (insulin ... - Finanzen.net,

Novo Nordisk Sues sanofi-aventis for Insulin Delivery Device ... Sep 22, 2005
...and 30% insulin aspart injection, [rDNA origin]), NovoLogÂ® (insulin aspart [rDNA origin] injection) and soon-to-be-launched LevemirÂ® (insulin detemir [rDNA ... - Yahoo! News (press release)

European Stocks Fall in Week on Oil; Ericsson, Michelin Drop Aug 27, 2005
...patients with diabetes. Novo competes in the $14 billion insulin market with its Levemir compound, which acts for 24 hours. OMV AG ... - Bloomberg

Novo Nordisk A/S Interim Results Aug 11, 2005
...increased by 8% in local currencies and by 9% in Danish kroner, with growth primarily driven by the portfolio of insulin analogues, including Levemir(R), which ... - ArriveNet (press release),

Novo Nordisk Perks Up Aug 12, 2005
Analog insulins continue to gain share in the insulin market, and with the June approval of Levemir, Novo Nordisk now has a complete suite of analogs for the ... - Motley Fool